文献速递脊柱外科

BMP/激活素A嵌合体在非人灵长类中低浓度诱导后外侧脊柱融合

A BMP/Activin A Chimera Induces Posterolateral Spine Fusion in Nonhuman Primates at Lower Concentrations Than BMP-2.
PubMed 文献 · J Bone Joint Surg Am · 2021-01-01

本研究在非人灵长类无内固定后外侧融合模型中,比较了BMP-2/BMP-6/激活素A嵌合体(BV-265)与BMP-2的成骨效果。结果显示BV-265在显著低于BMP-2的浓度下即可实现成功的两节段融合,提示其可作为BMP-2的潜在替代方案。

要点

  • BV-265在0.25 mg/cm3(CM)或0.15-0.3 mg/cm3(PCM)浓度下可实现两节段后外侧融合。
  • BMP-2/ACS:MM在0.43 mg/cm3浓度下未能生成后外侧融合。
  • BV-265/CM的体内保留率高于BV-265/PCM,后者高于BMP-2/ACS。

核心结论

  • BV-265/CM或PCM可在非人灵长类无内固定后外侧融合模型中,以显著低于BMP-2/ACS:MM的浓度诱导融合。

研究设计与样本

  • 在26只猴的L3-L4和L5-L6或L3-L4-L5横突去皮质后外侧融合模型中,植入CM、BV-265/CM、BV-265/PCM或BMP-2/ACS:MM。
  • 另用大鼠肌肉袋模型和闪烁显像比较125I标记的BV-265/CM或PCM与BMP-2/ACS或BMP-2/缓冲液的体内保留。
  • 术后0、4、8、12、24周获取CT图像,处死后进行手法触诊、μCT或nCT及组织学分析。

主要发现

  • 125I标记BV-265/CM的保留率高于BV-265/PCM,其后依次为BMP-2/ACS和BMP-2/缓冲液。
  • CM、0.43 mg/cm3 BMP-2/ACS:MM和0.05 mg/cm3 BV-265/CM未能生成后外侧融合。
  • 0.15 mg/cm3 BV-265/CM或0.075 mg/cm3 BV-265/PCM部分有效;0.25 mg/cm3 BV-265/CM及0.15和0.3 mg/cm3 BV-265/PCM在12和24周生成成功的两节段后外侧融合。

关键数值与推荐

  • BV-265/CM有效融合浓度为0.25 mg/cm3,BV-265/PCM为0.15和0.3 mg/cm3。
  • BMP-2/ACS:MM在0.43 mg/cm3浓度下未实现融合。

临床怎么用

  • BV-265/CM和PCM可能以显著低于BMP-2/ACS:MM的浓度在人类中诱导后外侧融合,是潜在替代方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Supraphysiologic bone morphogenetic protein (BMP)-2 concentrations are required to induce spinal fusion. In this study, a BMP-2/BMP-6/activin A chimera (BV-265), optimized for BMP receptor binding, delivered in a recombinant human collagen:CDHA [calcium-deficient hydroxyapatite] porous composite matrix (CM) or bovine collagen:CDHA granule porous composite matrix (PCM), engineered for optimal BV-265 retention and guided tissue repair, was compared with BMP-2 delivered in a bovine absorbable collagen sponge (ACS) wrapped around a MASTERGRAFT Matrix (MM) ceramic-collagen rod (ACS:MM) in a nonhuman primate noninstrumented posterolateral fusion (PLF) model. METHODS: In vivo retention of 125I-labeled-BV-265/CM or PCM was compared with 125I-labeled-BMP-2/ACS or BMP-2/buffer in a rat muscle pouch model using scintigraphy. Noninstrumented PLF was performed by implanting CM, BV-265/CM, BV-265/PCM, or BMP-2/ACS:MM across L3-L4 and L5-L6 or L3-L4-L5 decorticated transverse processes in 26 monkeys. Computed tomography (CT) images were acquired at 0, 4, 8, 12, and 24 weeks after surgery, where applicable. Manual palpation, μCT (microcomputed tomography) or nCT (nanocomputed tomography), and histological analysis were performed following euthanasia. RESULTS: Retention of 125I-labeled-BV-265/CM was greater than BV-265/PCM, followed by BMP-2/ACS and BMP-2/buffer. The CM, 0.43 mg/cm3 BMP-2/ACS:MM, and 0.05 mg/cm3 BV-265/CM failed to generate PLFs. The 0.15-mg/cm3 BV-265/CM or 0.075-mg/cm3 BV-265/PCM combinations were partially effective. The 0.25-mg/cm3 BV-265/CM and 0.15 and 0.3-mg/cm3 BV-265/PCM combinations generated successful 2-level PLFs at 12 and 24 weeks. CONCLUSIONS: BV-265/CM or PCM can induce fusion in a challenging nonhuman primate noninstrumented PLF model at substantially lower concentrations than BMP-2/ACS:MM. CLINICAL RELEVANCE: BV-265/CM and PCM represent potential alternatives to induce PLF in humans at substantially lower concentrations than BMP-2/ACS:MM.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Seeherman HJ, Wilson CG, Vanderploeg EJ, et al. A BMP/Activin A Chimera Induces Posterolateral Spine Fusion in Nonhuman Primates at Lower Concentrations Than BMP-2. J Bone Joint Surg Am. 2021. PMID: 33950879. doi:10.2106/JBJS.20.02036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。